

22nd April 2026

Prolimmune Judgement and Settlement

Background

Holista Colltech Limited (ASX: HCT) (Company) advises that on 7 April 2026, the Supreme Court of Western Australia (Palmer J) delivered judgment in the matter of The Prolimmune Company, LLC v Holista Colltech Limited [2026] WASC 112, granting summary judgment in favour of The Prolimmune Company, LLC (Prolimmune).

The proceedings arose from a judgment entered on 23 January 2024 by the US District Court for the Southern District of New York in Proimmune's favour of US\$2,063,141.05, following findings that the Company breached minimum performance requirements under distribution agreements for its Immune Formulation 200® product. The US judgment was affirmed on appeal by the United States Court of Appeals for the Second Circuit on 20 February 2025.

Prolimmune subsequently commenced proceedings in the Supreme Court of Western Australia seeking to enforce the US judgment and applied for summary judgment. The Company opposed the application, relying on a cross-claim alleging misleading or deceptive conduct under section 18 of the Australian Consumer Law as a defence of equitable set-off. The Court rejected that defence and granted summary judgment.

Key Findings of the Court

The Court found that:

1. Prolimmune satisfied the common law requirements for recognition and enforcement of a foreign judgment in Australia.
2. The Company's evidence supporting its crossclaim was insufficient to establish a triable case
3. In any event, the cross-claim was insufficiently connected to give rise to equitable set-off, and equitable set-off is not an available defence to the enforcement of a foreign judgment

Judgment was entered in US dollars. The total judgment debt of US\$2,063,141.05 comprises the following components:

Component	Amount (USD)
Damages (First, Second and Fourth Contracts)	1,198,150.00
Pre-judgment interest (9% per annum)	668,973.55
Attorney's fees	196,017.50
Total judgment debt (23 January 2024)	2,063,141.05
Post-judgment interest (28 U.S.C. § 1961(a) at 4.81% p.a. from 23 January 2024)	Accruing

The Company's claim for misleading or deceptive conduct remains on foot as a separate proceeding.

Settlement

Following the judgment, the Board has resolved to accept a negotiated settlement with ProImmune to fully and finally resolve the judgment debt and all related claims.

The Board considers the settlement to be in the best interests of the Company and its shareholders, having regard to the judgment's outcome and the costs, risks, and uncertainties associated with ongoing litigation.

Key terms of the settlement are:

- Total settlement amount: US\$1,800,000
- Initial payment (within 7 days): US\$1,000,000
- Balance payment (on or before 14th July 2026): US\$800,000

The settlement amount of US\$1,800,000 represents a material discount to the Company's total judgment debt of US\$2,063,141.05, plus post-judgment interest accruing at 4.81% per annum from 23 January 2024 and legal fees to a total of US\$2,400,000

The Company has previously paid a US\$500,000 deposit, which is also part of the negotiated settlement.

The settlement agreement is being finalised. The Company has worked with ProImmune's counsel to finalize the formal settlement agreement and closing documents. Accordingly, the first payment of US\$1,000,000 is being made today.

Authorisation

This announcement has been authorised for release by the Board of Directors of Holista Colltech Limited.

-- ENDS --

About Holista Colltech Limited

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions, listed on the Australian Securities Exchange. The Company operates across four core business divisions: Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control Solutions.

Holista's portfolio includes market-leading nutritional supplements, patented low-GI food ingredients adopted by global food manufacturers, premium disease-free ovine collagen, and all-natural, non-toxic sanitizers for consumer and industrial use. These offerings reflect Holista's commitment to combining the best of nature and science to support healthier modern lifestyles.

With a strong track record of research, development, and commercialization, Holista has pioneered several proprietary technologies in the global health and wellness sector. The Company remains dedicated to delivering sustainable, science-backed solutions that enrich lives and promote better living worldwide.